APP and Alzheimer disease: Other evidence of the involvement of gangliosides in AD pathophysiology came from the observation that the inhibition of glycosylceramide synthase, which catalyzes the first step in glycosphingolipid biosynthesis, was correlated with a reduction of amyloidogenic processing of APP [238].